Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study Evaluating the Combination Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy Containing High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.

Trial Profile

Phase II Study Evaluating the Combination Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy Containing High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2018

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Dexamethasone
  • Indications B-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms MYLY
  • Most Recent Events

    • 05 Nov 2013 Planned end date changed from 1 Jan 2017 to 1 Jun 2017 as reported by ClinicalTrials.gov
    • 01 Oct 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 15 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top